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Abstract
Background: Infection rates in revision (second and subsequent) major joint arthroplasty continues to be a
significant issue with rates 2–3 times those of primary procedures. The effect of antibiotic and antiseptic prophylaxis
on outcomes for this type of surgery has not been adequately reviewed.
Methods: A systematic search of the main databases for randomized controlled trials (RCTs) evaluating antibiotics
and antiseptics was conducted to evaluate the predetermined endpoints of infection.
Results: There were five (5) RCTs identified that examined the effects of antibiotic and antiseptic prophylaxis on
infections after revision total hip arthroplasty [THA] (total of 304 participants) and total knee arthroplasty [TKA] (total
of 206 participants). For TKA, preoperative systemic intravenous (IV) antibiotic prophylaxis plus antibiotic cement
may be effective in reducing the incidence of infection in revision TKA at 8+ years. These results however should
be interpreted with caution due to the significant biases. For revision THA, there is no RCT evidence that
antibiotics/antiseptics have any effect on the infection rate.
Conclusions: There is a lack of high quality data demonstrating an effect of antibiotics or antiseptics on infection
rates in revision THA/TKA. Considering the rate of infections in revisions is 2-3X that of primary procedures and;
there is a consensus recommendation to use similar antibiotic and antiseptic regimens in both primary and revision
procedures, there is a need for high quality studies in revision THA/TKA.
Background
The use of antibiotic and antiseptic prophylaxis for pri-
mary total hip and knee arthroplasty (referred to going
forward as THA and TKA) has recently been examined in
a systematic review and meta-analysis of randomized con-
trolled trials [1]. In this analysis, it was found that pre-
operative systemic antibiotic prophylaxis is effective at
reducing the infection rate in primary THA (vs. placebo)
and that there is no high quality RCT evidence antibiotic
prophylaxis is effective at reducing the infection rates in
primary TKA. Additionally, it was found that the majority
of the US studies examining antibiotic prophylaxis were
published back in the 1980s and 1990s. As has been noted,
the incidence of diabetes and obesity has increased signifi-
cantly in these types of patients both for primary and revi-
sion THA/TKA [2, 3]; with diabetes and obesity being
known and statistically significant risk factors for infection
[4–7]. To date there has not been any sort of systematic
review of RCTs examining the effect of antibiotic and anti-
septic prophylaxis solely on revision THA and TKA.
There have been systematic reviews and meta-analysis
that have examined the effect of antibiotic prophylaxis on
primary and revision THA/TKA collectively [without sep-
arating them out] [8–10]. However, studies also acknow-
ledge the fact that the peri-prosthetic infection rate is 2–3
times higher in revision THA and TKA than in primary
THA/TKA. Additionally, other studies have stated that
patients are at a 9–13 times higher risk of infection in a
revision TKA/THA procedure than in a primary THA/
TKA [11]. Further, the infection rates in revision THA/
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TKA have also more than doubled from 1.4% in the
1991–1994 timeframe to 3.0% in the 2007–2010 time-
frame [3]. Despite the statistically significant higher infec-
tion rates seen in revision THA/TKA, surprisingly, the
current strong consensus is that perioperative antibiotic
prophylaxis should be the same for primary and unin-
fected revision THA/TKA [12].
The most common organisms for implant infection
are Staphylococcus aureus (50–65%) and Staphylococcus
epidermis (25–30%) [13, 14]. However there is also a risk
posed by nosocomial (hospital acquired) bacterial infec-
tions that are resistant to the antibiotics commonly used
prophylactically in implant surgery [15]. These hospital
acquired infections include Clostridium difficile (C. diff )
and methicillin-resistant Staphylococcus aureus (MRSA).
This is especially important in revision procedures as pa-
tients undergoing these procedures have an increased
risk of developing C diff infections due to their more ad-
vanced age and length of hospital stay (relative to pri-
mary THA/TKA procedures) [3].
In the US, over the 2006–2012 timeframe (most recent
data available on HCUP-Net), there has been a 29% in-
crease in the number of primary THA and TKA implant
procedures going from 700,000 in 2006 to 910,000 in 2012
[16]. During this same timeframe, there has been a 35% in-
crease in the number of revision THA and TKA implant
procedures (complete or partial revision) - going from
75,000 in 2006 to 104,000 in 2012 [16] (See Table 1). This
increase in revision procedures in excess of the increase in
the number of primary THA and TKA implants is likely
due to the prevalence of over 7 million people living with
THA and TKAs [17]. A main reason for revision has been
due to infection, with approximately 35% of large joint im-
plants (THA/TKA) being revised for this reason [16].
It is with these issues in mind that a systematic review
was undertaken of randomized controlled trials to exam-
ine the effect of antibiotics and antiseptics used peri-
procedurally during the revision THA/TKA procedure.
Specifically, the objective of this systematic review was
to determine if the application of, types of, route admin-
istered, timing, and dosage(s) of antibiotics and
antiseptics affected the outcome of infection rates seen
post-procedurally in revision THA and TKA.
Methods
Data sources and searches
The following electronic databases were searched:
 The Cochrane Wounds Group Specialized Register
(searched 31 March 2015);
 The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 3);
 The Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 1);
 The NHS Economic Evaluation Database (NHS
EED; 2014, Issue 1);
 Ovid MEDLINE (1948 to March Week 15, 2015);
 Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, 31 March 2015);
 Ovid EMBASE (1980 to 2015 Week 15);
 EBSCO CINAHL (1982 to 31 March 2015);
 Network Digital Library of Theses and Dissertations
(NDLTD)
Contacting corresponding authors of included trials
was attempted (where updated contact information
existed) in addition to the manufacturers and distribu-
tors of antibiotics (linezolid, quinupristin/dalfopristin,
daptomycin, tigecycline, telavancin and other antistaphy-
lococcal agents and antiseptics). The US Food and Drug
Administration (FDA) briefing documents used in the li-
censing of antistaphylococcal agents was also searched.
Citation lists of papers identified by the above strategies
for further reports of eligible studies were also checked.
The following journals were also hand searched:
 Journal of Bone and Joint Surgery (American volume)
(most recent six months up to 4 September 2015;
searched on 4 September 2015);
 Journal of Bone and Joint Surgery (British volume)
(most recent six months up to 4 September 2015;
searched on 4 September 2015);
Table 1 Total joint implants - primary and revision procedures US 2006-2012




2006 481,804 221,639 43,746 31,185 26,659 74,931 35.6%
2007 532,568 10.5% 244,247 10.2% 47,424 8.4% 34,174 9.6% 29,210 9.6% 81,598 35.8%
2008 591,493 11.1% 265,768 8.8% 56,013 18.1% 37,474 9.7% 33,986 16.4% 93,487 36.4%
2009 596,781 0.9% 274,090 3.1% 54,592 -2.5% 36,695 -2.1% 32,306 -4.9% 91,287 35.4%
2010 631,082 5.7% 290,959 6.2% 62,725 14.9% 41,340 12.7% 34,469 6.7% 104,065 33.1%
2011 617,823 -2.1% 293,117 0.7% 67,061 6.9% 45,212 9.4% 37,064 7.5% 112,273 33.0%
2012 610,409 -1.2% 299,590 2.2% 62,710 -6.5% 41,545 -8.1% 36,650 -1.1% 104,255 35.2%
Percent chg
2006 to 2012
26.7% 35.2% 43.4% 33.2% 37.5%
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 Clinical Orthopedics & Related Research (most
recent six months up to 4 September 2015; searched
on 4 September 2015) and;
 Journal of Antimicrobial Agents & Chemotherapy
(most recent six months up to 4 September 2015;
searched on 4 September 2015).
Hand searching the journals above was undertaken be-
cause of the time lag between their publication and
availability on electronic indexes.
In addition, ClinicalTrials.gov on 4 September 2015
were searched to identify any trials in process or recently
completed. Google was searched on 4 September 2015
using the search terms: mupirocin, antibiotic, prophy-
laxis, revision, and orthopedic. The first 8 pages of hits
were evaluated.
Search MeSH terms can be found in Additional file 1:
Appendix 1. Two review authors screened the titles and
abstracts of all studies identified by the search independ-
ently. Upon the verbal agreement of both review au-
thors, we obtained full text versions of all studies
identified as potentially relevant, and two review authors
assessed them independently against the inclusion cri-
teria. Any disagreement(s) between the two review
authors were resolved by discussion or adjudicated by a
third author.
Study selection
A systematic review of randomized controlled trials
(RCTs) was undertaken that investigated the effect of peri-
operative antibiotic prophylaxis with or without antisep-
tics, on outcomes related to surgical site infections (SSIs)
during revision THA or TKA replacement. As it relates to
definitions used in this analysis, THA/TKA revision pro-
cedures are performed for a number of reasons including:
mechanical loosening, dislocation, implant failure/break-
age, periprosthetic fracture, periprosthetic osteolysis, bear-
ing surface wear, and infection. We did not include
revision THA/TKA for infection as the treatment is anti-
biotics/antiseptics. We were specifically seeking the effect
of antibiotic/antiseptic prophylaxis in the future incidence
of infection. Additionally, revision THA/TKA procedures
are performed to revise all or some of the components
that make up the THA/TKA implant. In this analysis we
are defining a revision THA as the repeat (second time or
more) replacement of: the femoral implant; and/or the ac-
etabular (socket) component and/or; the acetabular liner
(composed of different materials but commonly polyethyl-
ene). Similarly, revision TKA is defined as the repeat (sec-
ond time or more) replacement of: the top/upper portion
of the tibial bone (tibial component); and/or the tibial in-
sert (composed of polyethylene); and/or the bottom por-
tion of the femoral bone (or femoral condyles termed the
femoral component); and/or the patellar components. It
also involved the removal of these implants without re-
placement. Implants that did not meet this definition of
THA and TKA were excluded. The years in which antibi-
otics and antiseptics were first introduced up to the
present were considered. All languages were considered.
The PRISMA and CONSORT guidelines were followed.
Two review authors screened the titles and abstracts
of all studies identified by the search independently.
Upon the agreement of both review authors, we ob-
tained full text versions of all studies identified as poten-
tially relevant, and two review authors assessed them
independently against the inclusion criteria. Any dis-
agreement(s) between the two review authors were
resolved by discussion or adjudicated by a third author.
Only full text versions of studies were considered (pub-
lished or unpublished). Abstracts and conference
proceedings were not considered, unless a full length
manuscript existed.
Data extraction and study quality assessment
A data extraction form was developed (See Additional
file 1: Appendix 1). One review author extracted the data
and a second review author validated the extracted data
(performed via written comments and verbally). If a
study had more than one publication, all versions were
considered in order to maximize data extraction, and
the primary publication was identified, along with the
secondary references. Where possible, the original inves-
tigators were contacted to request the missing data and
this was reported on qualitatively.
Assessment of risk of bias in included studies
Two review authors independently assessed each in-
cluded study using the Cochrane Collaboration tool for
assessing risk of bias [18]. This tool addresses six spe-
cific domains, namely sequence generation, allocation
concealment, blinding, incomplete outcome data, select-
ive outcome reporting and other issues (e.g. extreme
baseline imbalance; see Additional file 1: Appendix 1 for
details of the criteria on which judgements were based).
Blinding and completeness of outcome data were
assessed for each outcome separately. A ‘Risk of bias’
table was completed for each eligible study. Any dis-
agreement(s) amongst the review authors were discussed
to achieve a consensus.
Assessment of risk of bias using a ‘Risk of bias’ sum-
mary figure was evaluated, which presents all of the
judgements in a cross-tabulation of study by entry. This
display of internal validity indicates the weight the
reader may give the results of each study.
A separate examination of the results was reported ac-
cording to journal of publication and country to deter-
mine whether results differed according to the impact of
the journal (high versus low [19]; and country (location
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bias [20]. We also assessed studies other than RCTs (i.e.
quasi-RCTs) using the same criteria. We incorporated
the results of the ‘Risk of bias’ assessment into the re-
view through systematic narrative description and com-
mentary about each of the domains, leading to an
overall assessment of the risk of bias of the included
studies and a judgement about the internal validity of
the results.
Data synthesis and analysis
If trials included multiple intervention groups (e.g. dif-
ferent antibiotics), the goal was to split the shared con-
trol group into two or more groups with smaller sample
sizes, depending upon the number of interventions, and
include two or more comparisons.
Authors of papers that we identified only as abstracts
were contacted to determine whether the full paper had
been published in a peer-reviewed journal or was avail-
able from the author as an unpublished draft.
Assessment of reporting biases
Each primary outcome was reported separately. Further-
more, an assessment of publication bias (including a re-
view of unpublished studies); location bias (types of
journals) and language bias was made. The results of trials
were examined as favorable or not, with the assumption
that favorable results demonstrated a positive effect of
antibiotic prophylaxis in lowering the infection rate and
thus were published (versus not published) [21]. Location
bias refers to more significant results being published in
less-respected/low impact factor journals [19]. Lastly, an
analysis was made of the reporting of outcomes (reporting
bias) as identified below in the ‘Risk of bias’ tables.
Results
Results of the search
The electronic searches identified a total of 58 poten-
tially relevant reports. We obtained abstracts for all 58
for further review and evaluation. (See PRISMA Flow
Diagram, Fig. 1 for included and excluded studies).
Bibliographic reference checking of a Health Technol-
ogy Assessment [9], other systematic review articles [8],
and of current concept review articles [20, 21], identified
six additional articles [22–27]. Further hand searching of
a Cochrane Review [28] (found through the electronic
search) identified an additional study [29]. Hand search-
ing of journals for RCTs also identified three articles
[30–32]. Thus a total of ten studies were identified
through hand searches.
In total 68 study reports were identified.
Fig. 1 PRISMA flow diagram
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Included studies
Five RCTs met the inclusion criteria for the review [33–37].
Two authors were contacted to clarify questions on study
design [33] and the breakout of infections by revision
THA/TKA [37]. In Chiu [33], both the lead and co-authors
never responded to email queries. Phillips [37] responded
on 1 September 2015 that he did not have the time to pro-
vide additional information (thus a sensitivity analysis was
performed on the worst case scenarios to determine if a
statistical difference existed). All of the studies except one
(Chiu 2009) [33] were conducted in the US. All studies ex-
cept for one [36] were single center RCTs. Two studies
were >20 years old [34, 36]. Table 2 shows a breakout of
the studies by: comparison; outcome and total number of
patients. In total there were 510 patients.
For the included studies, the comparisons by type of
implant, along with summary data on trial design/meth-
odology, sample size, setting, baseline characteristics of
patients, and important differences see the Characteris-
tics of the included studies as found in Additional file 2:
Appendix 2.
Excluded studies
Excluded study – characteristics
Six studies were excluded as they were duplicates of other
studies. These duplicates were [32, 38–42]. Thirty one
studies were excluded as they were randomized trials per-
formed on primary THA and TKA only [22, 25, 26, 27,
31, 43–67]. Nine studies were excluded due to the fact
that the number of revision THA/TKA procedures and
corresponding infections could not be broken out from
primary THA/TKA [29, 68–75]. Three studies were ex-
cluded as they were for revisions of infected primary
THA/TKA and the antibiotics administered were for
treatment and not for prophylaxis [76–78]. Three studies
were excluded due to the fact that the procedures were
not identified as a THA/THA but as an endoprosthesis
[79–81]. One study was excluded due to the fact that in
the 4 revision THA procedures identified, it could not be
determined to which treatment group the patients were
allocated to (flucloxacillin or cephaloridine antibiotic
prophylaxis [30]. One study was excluded because the
procedures being performed were adult orthopedic surgi-
cal cases which excluded total joint arthroplasty patients
[82]. Lastly, one study was excluded due to it being a
retrospective review of the timing of antibiotic prophylaxis
[83]. Thus in total 55 studies were excluded with reasons.
For further detail on excluded studies, see the Characteris-
tics of excluded studies as found in Additional file 2: Ap-
pendix 2.
Risk of bias in included studies
Generation of the randomization sequence
In the trial with the largest number of patients [33], the
risk of bias for randomization was high, considering the
use of an “odd-even” allocation. In 3 of the trials, the
randomization scheme was clearly identified [35, 36, 37].
In one study, the randomization scheme was unclear [34].
Allocation concealment
In all of the trials it was unclear as to when allocation to
the treatment occurred.
Blinding (performance bias and detection bias)
In 3 of the trials [33, 35, 37] the clinician performing the
procedures and/or the patient were aware of which
treatment group they were allocated to. In 4 of the trials
[33, 34, 35, 36] it was unclear if the clinician assessing
for the outcome of infection was aware of which treat-
ment group the patient was allocated to.
Incomplete outcome data (attrition bias)
In 3 of the trials there was a high risk of bias related to at-
trition of patients on follow up [33, 35, 36]).
Selective reporting (reporting bias)
In 2 of the studies the risk of selective reporting was
high. In DeBenedictis [34], adverse drug reactions identi-
fied as an outcome in the methods section were not re-
ported on in the results section. In Phillips 2014,
infection and adverse events at 12 months was identified
as an endpoint in the methods section but only 3 months
Table 2 Comparisons made in RCTs on the outcome of infection
Number patients
Study Comparison Outcome Revision THA Revision THA
Chiu 2009 Antibiotic impregnated bone cement vs. none Infection >8 year follow-up 183 0
DeBenedictis 1984 1st vs. 2nd generation cephalosporin Infection 12 months 1
Mauerhan 1994 1st vs. 2nd generation cephalosporin Infection 12 months 62 132
Jacobson 2005 DuraPrep plus Ioban drape vs. povidone iodine antiseptic 30 day infection 11 9
Phillips 2014 5 day pre-op mupirocin nasal nare application vs. 2 hour
pre-op povidone iodine antiseptic
3 month infection 48 64
Total 304 206
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of follow up on infections and adverse events were re-
ported on in the results section.
Other potential sources of bias
In 3 of the trials there was a high risk of other bias due
to: DeBenedictis 1984 [34] - financial assistance from a
manufacturer of one of the antibiotics used; Jacobson
2005 [35] - financial assistance from a manufacturer for
the antiseptic used and in the writing of the manuscript;
and Phillips 2014 [37] - the manufacturer of one of the
products used providing a research grant for the study.
Risk of bias is found in Fig. 2 (Risk of bias summary) and
Fig. 3 (risk of bias graph) and; as well Additional file 2:
Appendix 2.
Effects of interventions (main outcome of incidence of
infection)
Statistically significant findings (using Fisher exact test)
were identified when comparing vancomycin impreg-
nated cement along with IV cefazolin to IV cefazolin in
revision TKA procedures [33] (P = 0.0129). Non-
significant findings on the 1 year outcome of infection
were identified in comparing 1st generation vs. 2nd gen-
eration cefazolin in revision TKA [36] (RR = 0.29; 95%
CI: 0.01 to 6.95; P = 0.45). Further as it relates to the use
of mupirocin vs. povidone iodine (PI) nasal antisepsis
there was no statistically significant difference in the
outcome of infection at 30 days for either revision THA
or revision TKA. For this particular analysis, since we
were unable to obtain the results from the authors of
the article [37] we performed a sensitivity analysis on
the incidence of infection in either treatment group
(mupirocin vs. PI) using the worst case scenarios on the
incidence of infections. In all cases, the differences did
not reach statistical significance.
Discussion
Based on the available data and its relative “poor quality”
(i.e. studies with significant biases), no recommendations
can be made regarding antibiotic/antiseptic prophylaxis
regimens for revision THA/TKA. There is a worrisome
lack of data demonstrating any effect of prophylactic
antibiotic and antiseptic use on the incidence of infec-
tion in revision THA/TKA. In total there were 510 revi-
sion THA/TKA patients who could be identified in any
sort of randomized trial. Additionally, 183 of these 510
patients come from a trial that is considered poorly de-
signed from a randomization standpoint [18].
Fig. 3 Risk of bias graph
Fig. 2 Risk of bias summary
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Considering the infection rate in revision THA and
TKA is significantly higher than that in primary THA/
TKA [7, 8] and; that the consensus recommendation by
the Orthopaedic Research Society [12] is that the pre-
operative antibiotic regimens should be no different be-
tween primary and revision THA/TKA - there appears to
be no effective prophylaxis regimen(s) that can reduce the
infection rate seen in revision THA/TKA. It should be
noted that this consensus recommendation has been
made using non-randomized studies [12], which thus may
render these conclusions questionable.
In the past, the meta-analytic examination of prophylac-
tic antibiotics and antiseptics for preventing infection in
primary and revision THA/TKA had not been broken out
from primary and revision THA/TKA procedures. For
this particular analysis it meant that 9 studies had to be
excluded from the overall analysis due to this [29, 68–75].
Additionally, THA and TKA have also not been broken
out on the outcome of infection [1] - THA and TKA have
traditionally been combined on the outcome of infection.
This is also a concern considering the fact that twice as
many people receive primary TKA vs. THA; are 20% heav-
ier and live 25% longer than they did back in the late
1980s–1990s; are more physically active; that diabetes is 4
times as prevalent in the US vs. 25 years ago [84] and; that
diabetes along with obesity are risk factors for infection.
[4–7]. This likely means at many patients will outlive their
primary THA/TKA, will be sicker and require a revision
procedure.
Conclusions
This analysis supports the contention that more studies
need to be initiated examining; what if any antibiotic/anti-
septic prophylactic regimen(s) are effective at reducing the
infection rate in revision THA/TKA. A potentially reason-
able place to start, based on the results from Chiu 2009
[33], is with the use of antibiotic impregnated cement plus
IV antibiotics in revision TKA and; engaging in a trial that
is randomized appropriately with blinding of clinical as-
sessors (both issues with Chiu 2009 [33]). Further there
appears to be some clinical benefit in using antibiotic im-
pregnated bone cement in primary THA or TKA for re-
ducing the infection rate based on a recent systematic
review and meta-analysis [85] and in a recent systematic
review [10]. These analyses however, included non-
randomized studies but may indicate a potential effect of
antibiotic cement in revision THA/TKA [10]. There are
also several studies being undertaken which examine the
use of intraoperative local antibiotic administration in re-
vision TKA [86] (NCT02020031); preoperative antisepsis
in revision THA/TKA [87] (NCT02469311) and; betadine
lavage intraoperative and just prior to surgical closure in
revision TKA [88] (NCT01175044). The numbers of pa-
tients involved in some of these are likely to be too small
to demonstrate any statistically significant effect [86].
There are also no studies examining next generation anti-
biotics specifically for revision THA/TKA. Additional
RCT studies on antibiotic/antiseptic prophylaxis in revision
THA/TKA should be easier to undertake as the pool of po-
tential patients to include increases each year (Table 1) and
the incidence of infections in revision THA/TKA is 2–3
times that of primary THA/TKA [7, 8].
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